Wall Street analysts are raising price targets for Abbott Laboratories following strong second-quarter 2026 financial results. The company reported a 13% increase in sales. Management also raised its full-year adjusted earnings per share forecast.
Growth in the Medical Devices segment remains a primary driver for the positive outlook. The FreeStyle Libre continuous glucose monitor continues to lead the diabetes care business. Additionally, the recent acquisition of Exact Sciences expands the company's presence in cancer screening.
TD Cowen, Citi, and Wolfe Research recently issued higher price targets or rating upgrades. These firms highlight accelerating growth across core segments as a key factor.